Pharmanovia’s Post

🌟 Excited to be a speaker at the Biosimilars LatAm - Brazil 2024, In-person forum on August 21 & 22 at Pullman Sao Paulo Ibirapuera! 🌟 I'll be sharing insights on the panel session "Economic Impacts of Biosimilar Administration in Brazil: Cost Savings, Access, and Market Dynamics." #Brazil should follow other countries in Europe and across the globe, not only in regulatory analysis but also in medical adoption of #biosimilars, to broaden its experience and thus improve patient access. Join us to explore how the widespread use of biosimilars can lead to substantial savings, foster market competition, and expand accessibility to vital therapies. Join us for an insightful discussion! https://lnkd.in/dnuyqU74 organised by @jack-leckerman #BiosimilarsLatAm #Brazil2024 #HealthcareInnovation #BrazilHealthcare #EconomicImpacts #BrazilBiotech

As MedTech stocks continue to feel pressure from GLP-1 drugs for obesity, MedTech companies are increasingly tasked with articulating the value of their products. In our latest blog, IQVIA MedTech discusses current market shifts, and explains how IQVIA can offer crucial insights into the dynamics of GLP-1 markets and patient profiles at a global, national, and regional level. Read now. https://bit.ly/3YfCcNr #GLP1 #MedTech Authors: Christopher Ludwig and Michelle Edwards

🔔 Swedish Healthcare Alliance in Eurasia: Industry approach synergy for deepened partnerships I am delighted to announce the official launch of the #SwedishHealthcareAlliance in Eurasia. This initiative aims to create a platform for in-depth partnerships between medical professionals, academia, industry and government across the healthcare spectrum. Coordinated by Business Sweden in collaboration with the Embassy of Sweden in Astana, the Alliance boasts Members such as AstraZeneca, Sobi - Swedish Orphan Biovitrum AB (publ), Acino. Alliance mission is to cultivate enduring partnerships that transcend sporadic exchanges, but ensure continuous and strategic collaboration and knowledge sharing between key stakeholders in healthcare. The Swedish Healthcare Alliance in Eurasia is open for new members: Swedish companies that work in pharmaceuticals, medical devices industries, digitalization of healthcare and related services and are looking into expanding in the dynamic Eurasia region are welcome to join. We believe that cooperation is the path to success in new advances in medical care, treatment and health management. Reach out to the Swedish Healthcare Alliance lead, Ekaterina Pravdina or Country Manager Dr. Mattias Lindgren (Ph.D.) to learn more about the activities under the Alliance umbrella. #SwedishHealthcareAllianceEurasia #Businessdevelopment #Healthcare #LifeScience #Medtech #InnovationPartnerships #BusinessSweden

Recently, Daniel Gilbert The Washington Post detailed a Senate hearing with Novo Nordisk’s CEO discussing why the company's drugs, Ozempic and Wegovy, are more expensive in the U.S. compared to other regions like Europe. This issue is a reminder of the broader challenges we face in our healthcare system.   New Ocean CEO, Hal Rosenbluth , and Chief Marketing and Strategy Officer, Marnie Hall, found a poignant datapoint in their book “Hypochondria: What's Behind the Hidden Costs Healthcare Costs in America.”    “The United States spends three and four times more than other high-income countries, such as Japan and New Zealand, but has the lowest life expectancy at birth and highest death rates for treatable conditions. Health outcomes in the United States rank closer to countries with the worst health outcomes, such as Latvia and Turkey, which have bottom-of-the-barrel statistics when it comes to life expectancy after birth and managing diabetes.”    Despite this significant investment, outcomes lag behind, and patients aren’t receiving the care they deserve.   We must find a way forward. Over the past couple of years Mark Cuban Cost Plus Drug Company, PBC Drug Company, has introduced an innovative approach to making prescription medications more affordable and accessible. His model offers a glimpse into what the future of healthcare could look like—one where medication costs are transparent, and patients are empowered.   #Healthcare #DrugPrices #ChronicConditions #Diabetes   https://lnkd.in/erw9yWq4   ###

In an exclusive interview with BioPharma APAC, Rehan S., Executive Vice President of ZP Therapeutics, Zuellig Pharma shares his expert insights on the rapidly evolving healthcare landscape in Asia. With a focus on key trends in #druginnovation and #commercialization, particularly in areas such as #diabetes, #obesity, and #cardiovascularhealth, Saghir sheds light on the challenges and opportunities within this diverse and complex region. As Asia continues to witness significant changes driven by demographic shifts, urbanization, and rising non-communicable diseases, #ZPTherapeutics remains at the forefront of addressing these challenges through strategic partnerships, innovative approaches, and a deep understanding of the region’s unique needs. Read More: https://lnkd.in/dKnAbdEs

Major #PressRelease from Sigrid! 📰🗞 Today is not just another day; it’s a landmark moment in the fight against #Diabetes and #Obesity. Sigrid is thrilled to announce that we’ve surpassed the 50% Enrollment Milestone in our groundbreaking #SHINE Clinical Trial. As the largest study of its kind, #SHINE targets a critical health challenge by assessing the impact of our SiPore21® Gel in transforming #Diabetes and #Obesity management. This achievement isn't merely a step forward; it's a giant leap toward a new era of #health and #wellness. At the forefront of this revolution is our SiPore21® Silica "Molecular Sieves", embodying our relentless pursuit of #nonpharmaceutical, yet profoundly #effective solutions for #weight and #health management. Prof. Tore Bengtsson, Sigrid's Co-founder and CSO, remains at the heart of this innovation, asserting, “The SiPore® technology offers a unique non-pharmaceutical #alternative to #injectabledrugs for sustainable #bloodsugarmanagement, curbs #hungersensations, and reduces #bloating." This declaration is not just a testament to our #commitment but a signal to the world that change is on the horizon. Our gratitude extends to all who have contributed to this achievement. In this image, we spotlight Dr. #DagmarZakova, the top recruiter for the #SHINE clinical trial, whose unwavering #dedication has been pivotal in advancing medical research. Alongside her is our CEO, Sana Alajmovic, both emblematic of the #drive propelling us forward. Dive into the full press release here https://lnkd.in/d33KABqJ and become a part of this groundbreaking journey. #Like, #share, and #follow for the latest updates. We're not just envisioning a healthier future; together, we're building it! 💪 #SigridTherapeutics #SHINETrial #InnovationInHealth #FutureOfHealthcare #MedicalDevices #HealthTech

As MedTech stocks continue to feel pressure from GLP-1 drugs for obesity, MedTech companies are increasingly tasked with articulating the value of their products. In our latest blog, IQVIA MedTech discusses current market shifts, and explains how IQVIA can offer crucial insights into the dynamics of GLP-1 markets and patient profiles at a global, national, and regional level. Read now. https://bit.ly/3LaJMkE #GLP1 #MedTech Authors: Christopher Ludwig and Michelle Edwards

The South Korea #Pruritus_Therapeutics_Market was #valued at US$ 288.01 million in 2023 and is estimated to surpass the market #size of US$ 428.01 million by 2032, exhibiting a #CAGR of 4.50% during the #forecast period 2024–2032. 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐎𝐮𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐅𝐫𝐞𝐞: https://lnkd.in/eDHz6Khd Driven by the #country's aging population and high healthcare expenditure, South Korea's #pruritus therapeutics market is poised for #growth. With 14.9% of the #population over 65 and a commitment to addressing chronic skin conditions, the #demand for advanced #treatment options is on the rise. The nation's robust #healthcare infrastructure and government initiatives focused on #accessibility and #affordability further fuel market expansion. 𝐓𝐨𝐩 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐬 𝐒𝐨𝐮𝐭𝐡 𝐊𝐨𝐫𝐞𝐚 𝐏𝐫𝐮𝐫𝐢𝐭𝐮𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 AbbVie Amgen GSK Huons Co., Ltd. L&H company Novartis Sanofi Yuhan Corporation #PruritusTherapeutics #SkinCare #AgingPopulation #AffordableHealthcare #ChronicSkinConditions #HealthcareInfrastructure #AdvancedTreatments #InnovativeTherapies #AccessibleCare #MarketGrowth

"Twenty of the top 25 drugs Civica provides are currently in shortage nationally, but Civica is able to provide supply without interruption." - Dan Liljenquist, Chair of the Civica Rx Board, and Intermountain Health SVP, Chief Strategy Officer. "While Civica member hospitals have taken direct action to reduce their risk of shortages, many others have yet to take such steps." Putting Patients First "Innovative business models — like Civica’s — can lead to new markets and repair old and seemingly intractable market failures. Civica’s objective is to generate a societal return, improve medication reliability and affordability, and alleviate human suffering. It hopes to demonstrate that market solutions exist that put the needs of the patient first..." https://lnkd.in/ePJabCyR

🏥 France's Healthcare Revolution: Will CEESP Become the New NICE? 🌍 To combat rising drug prices, a report by France’s National Audit Office has recommended France’s cost-effectiveness body, CEESP, transforms into an organization which conducts independent cost-effectiveness analyses, like England's National Institute for Health and Care Excellence (NICE). Follow the link to the blog post written by Beth McCormick who discusses: • What is driving this potential transition? • Is this change feasible given the current size of the workforce at CEESP? • The impact of the joint EUHTA. • Will this impact patient access to therapies in France? • Key considerations for manufacturers launching in France, including potential evidence requirements, launch timelines, and price implications. 👉 Read the full analysis here: https://lnkd.in/eqiE29Ga 💬 What are your thoughts on France potentially adopting a NICE-like model? How might it reshape the landscape for drug pricing and patient access in France? #P4AInsights #CostEffectiveness #DrugPricing #HTAReform #HealthEconomics #NICEModel #PRMA #HTA #Oncology #InnovativeTherapies #CGT #MarketAccess #PatientAccess #CEESP #CESP #NICE #EUjHTA #jointEUHTA #France #UK